Alex Tipping
About Alex Tipping
Alex Tipping is an Associate Director at Adaptimmune, where he has worked since 2019, leading tumour biopsy analyses for clinical trials in adoptive immunotherapy. With a background in molecular genetics and extensive experience in cancer research, he has held various academic and research positions over the years.
Work at Adaptimmune
Alex Tipping has been serving as Associate Director at Adaptimmune since 2019. In this role, he leads tumor biopsy analyses related to clinical trials of the company's adoptive immunotherapy programs. Prior to his current position, he worked as Principal Scientist II at Adaptimmune from 2015 to 2019, contributing to the development of innovative cancer therapies.
Education and Expertise
Alex Tipping has extensive expertise in translational sciences, particularly in flow cytometry and assays of cell function. His research has focused on RNA sequencing, including RNA-seq of populations and single-cell RNA-seq, particularly in the context of clinical trials for cancer immunotherapy. He is interested in discovering new therapeutic targets using emerging technologies.
Background
Alex Tipping's academic career includes significant positions at several prestigious institutions. He worked as a Postdoctoral Research Associate at King's College London from 1996 to 2000, followed by a role as Investigator Scientist at the Medical Research Council/University of Oxford from 2003 to 2011. He also served as a Senior Research Associate at University College London from 2011 to 2013 and as a Postdoctoral Research Associate at Imperial College London from 2000 to 2003.
Achievements
Throughout his career, Alex Tipping has managed projects that involve advanced methodologies in cancer research. His work has contributed to understanding the molecular mechanisms of hematopoietic stem and progenitor cells. His leadership in clinical trial analyses at Adaptimmune has been pivotal in advancing the company's immunotherapy programs.